Finding better ways to treat cancer
Finding better ways to
treat cancer
At Bolt, our mission is to harness the power of the immune system to improve lives and eradicate cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, which has evolved to recognize sequences associated with foreign invaders including bacteria, viruses, and fungi. Our various approaches use pattern recognition receptors in the innate immune system to help the body recognize and eliminate tumor cells.
At Bolt, our mission is to harness the power of the immune system to improve lives and eradicate cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, which has evolved to recognize sequences associated with foreign invaders including bacteria, viruses, and fungi. Our various approaches use pattern recognition receptors in the innate immune system to help the body recognize and eliminate tumor cells.
Our Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform has generated a number of product candidates, many through collaborations, combining various tumor-targeting antibodies and our immune-stimulating payloads.
Our Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform has generated a number of product candidates, many through collaborations, combining various tumor-targeting antibodies and our immune-stimulating payloads.
BDC-4182 is our next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, and other tumor types. Enrollment is currently open in the Phase 1 dose-escalation trial.
BDC-4182 is our next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, and other tumor types. Enrollment is currently open in the Phase 1 dose-escalation trial.
Bolt is pioneering a new approach, using myeloid cells and the innate immune system to create targeted immunotherapies. Additional programs are available for partnering, including a macrophage-targeting agonist antibody with Phase 1 data and two preclinical ISACs.
Bolt is pioneering a new approach, using myeloid cells and the innate immune system to create targeted immunotherapies. Additional programs are available for partnering, including a macrophage-targeting agonist antibody with Phase 1 data and two preclinical ISACs.
Our passionate and seasoned team of inventors, scientists and biotech builders is dedicated to generating breakthroughs for patients. Because our patients cannot wait.
Our passionate and seasoned team of inventors, scientists and biotech builders is dedicated to generating breakthroughs for patients. Because our patients can’t wait, and they shouldn’t have to.
